Home

Laurent Fischer

CIK 1379344 · CEO, PRESIDENT AND DIRECTOR · last filed 2026-09-11

Laurent Fischer is a CEO, PRESIDENT AND DIRECTOR who has filed 50 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for ATAI, was dated Sep 11, 2026. Across all open-market trades the lifetime net is +$899.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $967.8K across reported positions. 3 SEC filings were submitted jointly with ATAI Life Sciences N.V.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$967.8K

Companies

6

Total Filings

50

Lifetime Open-Market Net

$899.9K

Filer Profile

Reported Address
C/O ADVERUM BIOTECHNOLOGIES, INC.
100 CARDINAL WAY
REDWOOD CITY, CA 94063
Related Filers
ATAI Life Sciences N.V. — 3 joint filings, latest 2025-06-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ATAI Director — $7.35 — $0 4 2026-09-11
MIRM Director 10,727 $90.22 $967.8K $69.0K 10 2026-06-17
Adverum Biotechnologies, Inc. (ADVM) Delisted CEO, PRESIDENT AND DIRECTOR 522,666 $4.36 $2.28M $830.9K 21 2025-12-10
CTI BIOPHARMA CORP (CTIC) Delisted Director — $9.09 — $0 8 2023-06-26
Tobira Therapeutics, Inc. (TBRA) Delisted Chief Executive Officer — — — $0 3 2016-01-14
PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Director — — — $0 3 2008-06-30

Recent Filings

50 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-11 ATAI Disp (D) — $0 EDGAR
2026-06-17 MIRM Grant (A) — $0 EDGAR
2026-06-08 ATAI Grant (A) — $0 EDGAR
2026-06-02 MIRM Exer (M) +3,977 $0 EDGAR
2025-12-10 Adverum Biotechnologies, Inc. (ADVM) Delisted Mixed −249,179 $630.0K EDGAR
2025-12-08 Adverum Biotechnologies, Inc. (ADVM) Delisted Buy (P) +128,699 $553.9K EDGAR
2025-06-27 ATAI Grant (A) — $0 EDGAR
2025-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Mixed — $0 EDGAR
2025-06-02 MIRM Grant (A) — $0 EDGAR
2025-05-16 Adverum Biotechnologies, Inc. (ADVM) Delisted Sell (S) −9,126 -$18.3K EDGAR
Showing 1–10 of 50
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.